Clinical Trials Logo

Filter by:
NCT ID: NCT04646044 Completed - Covid-19 Clinical Trials

A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19

Start date: November 13, 2020
Phase: Phase 1
Study type: Interventional

The main purpose of this phase-1b, multicenter, randomized double-blind, placebo-controlled, trial is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of bempegaldesleukin (BEMPEG; NKTR-214) in combination with standard of care (SOC) in adult patients with mild COVID-19 (coronavirus disease 2019). The trial will also define the recommended phase 2 dose (RP2D) of bempegaldesleukin in patients with mild COVID-19.

NCT ID: NCT04646018 Completed - Low Back Pain Clinical Trials

The Effect of Lumbopelvic Non-Thrust Spinal Manipulation on Individuals With Low Back Pain

Start date: May 20, 2020
Phase: N/A
Study type: Interventional

The purpose of this experiment is to determine the effects of a non-thrust manipulation procedure on muscle function, spinal mobility, and pain level on those experiencing low back pain (LBP) in a sample of individuals who identify English as their primary language. The rationale for this language criterion is provided in Section 9:F of this application. Muscle function will be measured via the muscle thickness of a deep spinal stabilizing muscle (multifidus, MF) while in both a resting state and during a maximum voluntary contraction (MVC). Spinal mobility will be measured as the active range of motion of both forward and backward trunk bending. Pain level will be a self-report measure recorded during rest and active range of motion. Hypothesis 1: A non-thrust manipulation procedure will increase the thickness of the sacral multifidus both at rest and during a maximum voluntary contraction Hypothesis 2: A non-thrust manipulation procedure will result in greater low back active range of motion. Hypothesis 3: A non-thrust manipulation procedure will result in a reduction in the participant's self-reported pain levels both at rest and during active range of motion movements.

NCT ID: NCT04645953 Completed - Clinical trials for Cyclic Vomiting Syndrome

Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome

Start date: February 11, 2021
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, double-blind, parallel group, placebo-controlled, efficacy and safety study of adult outpatients diagnosed with CVS and experiencing recurring episodes of stereotypical vomiting.

NCT ID: NCT04645940 Completed - Drug Interaction Clinical Trials

Fruquintinib Food Effect and Proton Pump Inhibitor Study

Start date: September 24, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this is to evaluate the effect of food and the effect of a proton pump inhibitor (rabeprazole) on the pharmacokinetics of fruquintinib.

NCT ID: NCT04645797 Completed - Clinical trials for Advanced Colorectal Carcinoma

A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions

Start date: January 20, 2021
Phase: Phase 1
Study type: Interventional

A Phase 1 dose escalation study to evaluate APR003 in patients with advanced colorectal cancer (CRC) with malignant liver lesions

NCT ID: NCT04645667 Completed - Acute GVHD Clinical Trials

Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant (HCT)

Start date: February 1, 2021
Phase:
Study type: Observational

The purpose of this research study is to evaluate tacrolimus plasma concentrations in patients who will undergo an allogeneic hematopoietic stem cell transplant (HCT). The study aims to identify associations between plasma concentrations, baseline demographic characteristics, clinical lab parameters, and genetic factors. These associations will help clinicians determine the best starting dose for tacrolimus in order to minimize risks of aGVHD and tacrolimus-induced toxicities.

NCT ID: NCT04645524 Completed - Clinical trials for Obstructive Sleep Apnea

Crossover Trial of AD182 and AD504 in Obstructive Sleep Apnea

Start date: December 1, 2020
Phase: Phase 2
Study type: Interventional

This is a randomized, 3-period, placebo-controlled, crossover study to examine the efficacy and safety of AD182 and AD504 versus placebo in patients with obstructive sleep apnea.

NCT ID: NCT04645342 Completed - Atrial Fibrillation Clinical Trials

Wire Instrumentation Using Radiofrequency Energy to Impact Transseptal Efficiency

WIRE-IT
Start date: November 30, 2020
Phase: N/A
Study type: Interventional

This is a randomized controlled trial examining whether Baylis's Versacross RF wire versus the conventional Baylis RF needle is better at puncturing through a thin wall in the heart (called "transseptal puncture") as measured by time to successful transseptal puncture, during cardiac ablation procedures.

NCT ID: NCT04645173 Completed - Cardiac Disease Clinical Trials

Comparison of Participants Who Received a CanGaroo® Envelope, TYRX™ Envelope, or no Envelope During CIED Implantation

HEAL
Start date: February 2, 2021
Phase:
Study type: Observational

The objective of this study is to gather information on participants returning at time of CIED change-out or revision who underwent a device implantation with either a CanGaroo® envelope, TYRX™ envelope, or no envelope.

NCT ID: NCT04645134 Completed - Aging Clinical Trials

Physical Activity and Cognitive Function in Older Adults: A Novel Role for GPLD1

BrainFit
Start date: April 1, 2021
Phase:
Study type: Observational

The investigators are conducting a cross-sectional, observational study to investigate whether plasma GPLD1 concentrations are associated with higher cognitive function and better brain structure and function in two groups of older adults with high or low levels of physical activity.